Welcome to Genmab

Engineering a
transformative tomorrow

As a leading international biotechnology company, we believe in the transformative power of science and technology. Science is not only our bedrock, it is our inspiration. We believe in improving the lives of patients with cancer by creating and developing innovative and differentiated antibody therapeutics that will transform the future of cancer treatment. We are Genmab.

Learn more

Pipeline

Transforming the future of cancer treatment

Cancer presents constant challenges in our society—from advancing drug development to fulfilling the unmet medical needs of patients. At Genmab, we have an appreciation for the power of the human immune system that gives us a unique perspective on how to respond and find solutions. That’s why we are focused on harnessing the immune system’s natural ability to fight against diseases to create therapeutics that have the potential to transform how cancer is treated.

See our products

Our Technology Platforms

Pioneering the next generation of antibody platforms

With an in-depth knowledge of antibody biology, we discover, develop and select the best possible antibody products. This relentless drive to innovate and advance the process of antibody discovery has led to our proprietary antibody technologies.

See our science at work

LATEST NEWS

Genmab achieves USD 40 million milestone in collaboration with AbbVie

Genmab announced today that it has reached the first milestone in its collaboration with AbbVie, triggered by progress in the Phase 3 study of epcoritamab in diffuse large B-cell lymphoma.

Read the Company Announcement

We turn science into medicine. We use our deep antibody expertise to create cancer therapeutics with the potential to improve patients’ lives.

Load more

Join our mission to transform the future of cancer treatment.

Learn about career opportunities

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.